Marchés français ouverture 1 h 24 min

Merck & Co., Inc. (MRK)

NYSE - NYSE Prix différé. Devise en USD
Ajouter à la liste dynamique
100,18-1,25 (-1,23 %)
À la clôture : 04:00PM EST
100,18 0,00 (0,00 %)
Échanges après Bourse : 07:59PM EST

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - General
Employés à temps plein67 000

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Robert M. Davis J.D.Chairman, President & CEO6,08M6,77M1967
Ms. Caroline LitchfieldExecutive VP & CFO2,8MS.O.1969
Ms. Jennifer L. ZacharyExecutive VP & General Counsel2,73M3,46M1978
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories3,44MS.O.1962
Mr. Chirfi GuindoSenior VP & Chief Marketing Officer for Merck Human Health1,54MS.O.1966
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital OfficerS.O.S.O.1969
Mr. Peter DannenbaumVice President of Investor RelationsS.O.S.O.S.O.
Lisa LeCointe-CephasSenior VP and Chief Ethics & Compliance OfficerS.O.S.O.1982
Ms. Cristal N. DowningExecutive VP and Chief Communications & Public Affairs OfficerS.O.S.O.1970
Mr. Steven C. MizellExecutive VP & Chief Human Resources OfficerS.O.S.O.1960
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merck & Co., Inc. en date du 28 novembre 2023 est 4. Les scores principaux sont Audit : 5; Société : 6; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.